School of Medicine , University of California, Riverside , Riverside , CA , USA.
School of Medicine , Saint Louis University , St. Louis , MO , USA.
J Dermatolog Treat. 2018 Jun;29(4):347-352. doi: 10.1080/09546634.2017.1395796. Epub 2017 Nov 10.
The development of biologic agents directed against distinct cytokines and receptors has advanced the therapeutic options available for psoriasis patients. Evidence from preclinical studies suggests that IL-17 may contribute to the pathogenesis of psoriasis. The objective was to review the safety and efficacy profile for each IL-17 inhibitor by evaluating phase III clinical trial data. We reviewed the results of phase III clinical trials for the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab. At week 12, the proportion of patients reaching Psoriasis Area and Severity Index (PASI 75) was above 60% for the most efficacious dose of each agent with favorable and comparable safety profiles. The most commonly reported adverse events were nasopharyngitis, headache, and upper respiratory tract infection. The clinical improvement among psoriasis patients on IL-17 inhibitors is similar or superior to the improvement seen with commercially produced biologic agents available accompanied by a favorable short-term safety profile. The results of the phase III trials indicate that IL-17 inhibitors are effective therapeutic options for psoriasis patients.
针对不同细胞因子和受体的生物制剂的发展为银屑病患者提供了更多的治疗选择。临床前研究证据表明，IL-17 可能参与银屑病的发病机制。本研究旨在通过评估 III 期临床试验数据，对每种 IL-17 抑制剂的安全性和疗效概况进行综述。我们对 secukinumab、ixekizumab 和 brodalumab 这三种 IL-17 抑制剂的 III 期临床试验结果进行了回顾。在第 12 周时，每种药物最有效的剂量均有超过 60%的患者达到银屑病面积和严重程度指数（PASI75），且具有良好的、可比的安全性。最常见的不良反应为鼻咽炎、头痛和上呼吸道感染。接受 IL-17 抑制剂治疗的银屑病患者的临床改善与现有商业化生物制剂相当或更优，且具有良好的短期安全性。III 期试验结果表明，IL-17 抑制剂是银屑病患者有效的治疗选择。
